PS341 inhibits hepatocellular and colorectal cancer cells through the FOXO3/CTNNB1 signaling pathway

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Yang, Zhao ^a,b,f   Liu, Shengwu ^c,d   Zhu, Mingao ^e   Zhang, Hong ^e   Wang, Ji ^e   Xu, Qian ^e   Lin, Kaisu ^e   Zhou, Xiumin ^a   Tao, Min ^a   Li, Chong ^a,f   Zhu, Hong ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^b INSTITUTE OF MICROBIOLOGY   (China)

^c HARVARD MEDICAL SCHOOL   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e THE SECOND AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^f INSTITUTE OF BIOPHYSICS   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; BORTEZOMIB; CTNNB1 PROTEIN, HUMAN; FOXO3 PROTEIN, HUMAN; TRANSCRIPTION FACTOR FKHRL1;

ANIMAL; CELL MOTION; CELL PROLIFERATION; COLORECTAL NEOPLASMS; DRUG EFFECTS; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION; GENETICS; HUMAN; LIVER NEOPLASMS; METABOLISM; MOUSE; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE; TUMOR INVASION;

ANIMALS; BETA CATENIN; BORTEZOMIB; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; COLORECTAL NEOPLASMS; EPITHELIAL-MESENCHYMAL TRANSITION; FORKHEAD BOX PROTEIN O3; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; MICE; NEOPLASM INVASIVENESS; SIGNAL TRANSDUCTION;

EID: 84959432364     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep22090     Document Type: Article

References (48)

1. Siegel, R., Ma, J., Zou, Z. & Jemal, A. Cancer statistics, 2014. CA Cancer J Clin 64, 9-29 (2014).
2. El-Serag, H. B. Hepatocellular carcinoma. N Engl J Med 365, 1118-27 (2011).
3. Scudellari, M. Drug development: try and try again. Nature 516, S4-6 (2014).
4. Wilhelm, S. et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 5, 835-44 (2006).
5. Guidetti, A. et al. Phase II study of sorafenib in patients with relapsed or refractory lymphoma. Br J Haematol 158, 108-19 (2012).
6. Meriggi, F., Bertocchi, P. & Zaniboni, A. Management of potentially resectable colorectal cancer liver metastases. World J Gastrointest Surg 5, 138-45 (2013).
7. Fearon, E. R. Molecular genetics of colorectal cancer. Annu Rev Pathol 6, 479-507 (2011).
8. Schmoll, H. J. & Stein, A. Colorectal cancer in 2013: Towards improved drugs, combinations and patient selection. Nat Rev Clin Oncol 11, 79-80 (2014).
9. Chen, D., Frezza, M., Schmitt, S., Kanwar, J. & Dou, Q. P. Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives. Curr Cancer Drug Targets 11, 239-53 (2011).
10. Cavo, M. Proteasome inhibitor bortezomib for the treatment of multiple myeloma. Leukemia 20, 1341-52 (2006).
11. Shin, D. H., Chun, Y. S., Lee, D. S., Huang, L. E. & Park, J. W. Bortezomib inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated repression of hypoxia-inducible factor-1. Blood 111, 3131-6 (2008).
12. Mackay, H. et al. A phase II trial with pharmacodynamic endpoints of the proteasome inhibitor bortezomib in patients with metastatic colorectal cancer. Clin Cancer Res 11, 5526-33 (2005).
13. Kim, G. P. et al. An international, multicenter phase II trial of bortezomib in patients with hepatocellular carcinoma. Invest New Drugs 30, 387-94 (2012).
14. Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646-74 (2011).
15. Kessenbrock, K., Plaks, V. & Werb, Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 141, 52-67 (2010).
16. Lamouille, S., Xu, J. & Derynck, R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol 15, 178-96 (2014).
17. Xu, J., Lamouille, S. & Derynck, R. TGF-beta-induced epithelial to mesenchymal transition. Cell Res 19, 156-72 (2009).
18. Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57-70 (2000).
19. Lee, J. M., Dedhar, S., Kalluri, R. & Thompson, E. W. The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol 172, 973-81 (2006).
20. Bohnsack, B. L. & Hirschi, K. K. Nutrient regulation of cell cycle progression. Annu Rev Nutr 24, 433-53 (2004).
21. Beck, B. & Blanpain, C. Unravelling cancer stem cell potential. Nat Rev Cancer 13, 727-38 (2013).
22. Majumdar, A. et al. Hepatic stem cells and transforming growth factor beta in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 9, 530-8 (2012).
23. Sukowati, C. H., Rosso, N., Croce, L. S. & Tiribelli, C. Hepatic cancer stem cells and drug resistance: Relevance in targeted therapies for hepatocellular carcinoma. World J Hepatol 2, 114-26 (2010).
24. Takebe, N., Nguyen, D. & Yang, S. X. Targeting notch signaling pathway in cancer: clinical development advances and challenges. Pharmacol Ther 141, 140-9 (2014).
25. Botchkina, G. Colon cancer stem cells-from basic to clinical application. Cancer Lett 338, 127-40 (2013).
26. Ibrahem, S. et al. STAT3 paradoxically stimulates beta-catenin expression but inhibits beta-catenin function. Int J Exp Pathol 95, 392-400 (2014).
27. Kim, H. A. et al. Notch1 counteracts WNT/beta-catenin signaling through chromatin modification in colorectal cancer. J Clin Invest 122, 3248-59 (2012).
28. Li, H. et al. VGLL4 inhibits EMT in part through suppressing Wnt/beta-catenin signaling pathway in gastric cancer. Med Oncol 32, 83 (2015).
29. Liu, H. et al. FOXO3a modulates WNT/beta-catenin signaling and suppresses epithelial-to-mesenchymal transition in prostate cancer cells. Cell Signal 27, 510-8 (2015).
30. Liu, H. et al. Reduced expression of SOX7 in ovarian cancer: a novel tumor suppressor through the Wnt/beta-catenin signaling pathway. J Ovarian Res 7, 87 (2014).
31. MacDonald, B. T., Tamai, K. & He, X. Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell 17, 9-26 (2009).
32. Tenbaum, S. P. et al. beta-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer. Nat Med 18, 892-901 (2012).
33. Stan, S. D., Hahm, E. R., Warin, R. & Singh, S. V. Withaferin A causes FOXO3a- and Bim-dependent apoptosis and inhibits growth of human breast cancer cells in vivo. Cancer Res 68, 7661-9 (2008).
34. Bullock, M. D. et al. FOXO3 expression during colorectal cancer progression: biomarker potential reflects a tumour suppressor role. Br J Cancer 109, 387-94 (2013).
35. Kraus, S. et al. Expression of wingless-type mouse mammary tumor virus integration site family pathway effectors in lymphatic and hepatic metastases of patients with colorectal cancer: Associations with the primary tumor. Oncol Lett 10, 863-868 (2015).
36. Ravid, T. & Hochstrasser, M. Diversity of degradation signals in the ubiquitin-proteasome system. Nat Rev Mol Cell Biol 9, 679-90 (2008).
37. Geng, F., Wenzel, S. & Tansey, W. P. Ubiquitin and proteasomes in transcription. Annu Rev Biochem 81, 177-201 (2012).
38. Voorhees, P. M. & Orlowski, R. Z. The proteasome and proteasome inhibitors in cancer therapy. Annu Rev Pharmacol Toxicol 46, 189-213 (2006).
39. Nalepa, G., Rolfe, M. & Harper, J. W. Drug discovery in the ubiquitin-proteasome system. Nat Rev Drug Discov 5, 596-613 (2006).
40. Richardson, P. G., Mitsiades, C., Hideshima, T. & Anderson, K. C. Bortezomib: proteasome inhibition as an effective anticancer therapy. Annu Rev Med 57, 33-47 (2006).
41. Aggarwal, S. Targeted cancer therapies. Nat Rev Drug Discov 9, 427-8 (2010).
42. Llovet, J. M. et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359, 378-90 (2008).
43. Li, C. et al. Interferon-stimulated gene 15 (ISG15) is a trigger for tumorigenesis and metastasis of hepatocellular carcinoma. Oncotarget 5, 8429-41 (2014).
44. Teicher, B. A., Ara, G., Herbst, R., Palombella, V. J. & Adams, J. The proteasome inhibitor PS-341 in cancer therapy. Clin Cancer Res 5, 2638-45 (1999).
45. Tian, J. et al. New human hepatocellular carcinoma (HCC) cell line with highly metastatic potential (MHCC97) and its expressions of the factors associated with metastasis. Br J Cancer 81, 814-21 (1999).
46. Kikkawa, Y. et al. The LG1-3 tandem of laminin alpha5 harbors the binding sites of Lutheran/basal cell adhesion molecule and alpha3beta1/alpha6beta1 integrins. J Biol Chem 282, 14853-60 (2007).
47. Ye, B. et al. Cytosolic carboxypeptidase CCP6 is required for megakaryopoiesis by modulating Mad2 polyglutamylation. J Exp Med 211, 2439-54 (2014).
48. Wu, S. et al. Novel variants in MLL confer to bladder cancer recurrence identified by whole-exome sequencing. Oncotarget (2015).